The Committee for Medicinal Products for Human Use (CHMP) decided that Intelence’ s benefits are greater than its risks when used in combination with a boosted protease inhibitor and other antiretroviral medicines for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients.